Mark K. Oki's Insider Trades & SAST Disclosures
Mark K. Oki's most recent trade in Achieve Life Sciences Inc. was a trade of 10,000 Common Stock done at an average price of $2.9 . Disclosure was reported to the exchange on March 17, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mark K. Oki.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Achieve Life Sciences Inc. | Mark K. Oki | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.89 per share. | 17 Mar 2025 | 10,000 | 10,000 (0%) | 0% | 2.9 | 28,887 | Common Stock |
| Achieve Life Sciences Inc. | Mark K. Oki | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2024 | 168,000 | 168,000 | - | - | Performance Restricted Stock Unit (PRSU) | |
| Achieve Life Sciences Inc. | Mark Oki K. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2024 | 72,000 | 72,000 | - | - | Common Stock Options (right to buy) | |
| Aytu BioPharma Inc | Mark K. Oki | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2023 | 13,000 | 13,000 | - | - | Employee Stock Option (Right to Buy) | |
| Aytu BioPharma Inc | Mark K. Oki | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.23 per share. | 18 Nov 2022 | 90,000 | 190,000 (0%) | 0% | 0.2 | 20,700 | Common Shares |
| Aytu BioPharma Inc | Mark K. Oki | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2022 | 100,000 | 100,000 (0%) | 0% | 0 | Common Shares |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges